Stocks
Arcturus Therapeutics Holdings Financial Statements (ARCT) |
||||||||||
| Arcturus Therapeutics Holdingssmart-lab.ru | % | 2020 | 2021 | 2022 | 2023 | 2023 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 01.03.2021 | 01.03.2022 | 29.03.2023 | 31.12.2023 | 14.03.2024 | 14.03.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 9.54 | 12.4 | 205.8 | 169.9 | 157.7 | 115.1 | |||
| Operating Income, bln rub | -71.5 | -202.9 | 12.2 | -75.1 | -4.15 | -100.9 | ||||
| EBITDA, bln rub | ? | -71.8 | -200.4 | 11.7 | -75.1 | -1.20 | -96.1 | |||
| Net profit, bln rub | ? | -71.4 | -206.9 | 9.35 | -26.6 | -29.7 | -85.9 | |||
| OCF, bln rub | ? | -42.9 | -135.0 | 32.0 | -18.1 | 17.9 | ||||
| CAPEX, bln rub | ? | 1.74 | 3.41 | 7.73 | 2.90 | 2.17 | ||||
| FCF, bln rub | ? | -44.6 | -138.4 | 24.3 | -21.0 | 15.7 | ||||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| OPEX, bln rub | 81.1 | 215.2 | 193.6 | 245.0 | 158.9 | 215.3 | ||||
| Cost of production, bln rub | 55.9 | 171.9 | 143.1 | 0.000 | 2.96 | 54.3 | ||||
| R&D, bln rub | 57.8 | 173.8 | 147.8 | 192.1 | 109.0 | 167.2 | ||||
| Interest expenses, bln rub | 0.361 | 2.67 | 0.420 | 0.000 | 0.767 | 0.024 | ||||
| Assets, bln rub | 476.5 | 392.8 | 450.4 | 429.4 | 429.4 | 429.4 | ||||
| Net Assets, bln rub | ? | 396.6 | 228.2 | 270.3 | 281.6 | 278.5 | 278.5 | |||
| Debt, bln rub | 17.9 | 67.6 | 90.9 | 25.9 | 30.2 | 30.2 | ||||
| Cash, bln rub | 462.9 | 370.5 | 391.9 | 347.0 | 347.0 | 347.0 | ||||
| Net debt, bln rub | -445.0 | -302.9 | -301.0 | -321.1 | -316.8 | -316.8 | ||||
| Ordinary share price, rub | 43.4 | 37.0 | 17.0 | 31.5 | 31.5 | 19.0 | ||||
| Number of ordinary shares, mln | 20.3 | 26.3 | 26.4 | 26.6 | 26.6 | 26.6 | ||||
| Market cap, bln rub | 881 | 974 | 449 | 840 | 840 | 505 | ||||
| EV, bln rub | ? | 436 | 671 | 147 | 518 | 523 | 189 | |||
| Book value, bln rub | 397 | 228 | 270 | 282 | 279 | 279 | ||||
| EPS, rub | ? | -3.51 | -7.86 | 0.35 | -1.00 | -1.12 | -3.23 | |||
| FCF/share, rub | -2.20 | -5.26 | 0.92 | 0.00 | -0.79 | 0.59 | ||||
| BV/share, rub | 19.5 | 8.67 | 10.2 | 10.6 | 10.5 | 10.5 | ||||
| EBITDA margin, % | ? | -752.6% | -1 621% | 5.67% | -44.2% | -0.76% | -83.5% | |||
| Net margin, % | ? | -748.1% | -1 674% | 4.54% | -15.6% | -18.8% | -74.6% | |||
| FCF yield, % | ? | -5.06% | -14.2% | 5.41% | 0.00% | -2.50% | 3.10% | |||
| ROE, % | ? | -18.0% | -90.6% | 3.46% | -9.44% | -10.7% | -30.8% | |||
| ROA, % | ? | -15.0% | -52.7% | 2.08% | -6.19% | -6.92% | -20.0% | |||
| P/E | ? | -12.3 | -4.71 | 48.0 | -31.6 | -28.2 | -5.88 | |||
| P/FCF | -19.7 | -7.04 | 18.5 | -40.0 | 32.2 | |||||
| P/S | ? | 92.3 | 78.8 | 2.18 | 4.94 | 5.32 | 4.39 | |||
| P/BV | ? | 2.22 | 4.27 | 1.66 | 2.98 | 3.01 | 1.81 | |||
| EV/EBITDA | ? | -6.07 | -3.35 | 12.6 | -6.91 | -437.5 | -1.96 | |||
| Debt/EBITDA | 6.20 | 1.51 | -25.8 | 4.28 | 265.1 | 3.30 | ||||
| R&D/CAPEX, % | 3 321% | 5 102% | 1 912% | 3 758% | 7 697% | |||||
| CAPEX/Revenue, % | 18.3% | 27.6% | 3.75% | 0.00% | 1.84% | 1.89% | ||||
| Arcturus Therapeutics Holdings shareholders | ||||||||||
